Journal
LEUKEMIA
Volume 21, Issue 3, Pages 524-528Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.leu.2404511
Keywords
Hodgkin's lymphoma; mantle cell lymphoma; bortezomib; cytarabine; combination treatment
Categories
Ask authors/readers for more resources
Single-agent bortezomib, a potent, selective and reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL). Objective response is achieved in up to 45% of the patients; however, complete remission rates are low and duration of response proved to be short. These limitations may be overcome by combining proteasome inhibition with conventional chemotherapy. Here we present two case reports and in vitro data suggesting synergistic efficacy of bortezomib combined with cytarabine in MCL. Interestingly, efficacy in vitro correlated with sequence of treatment, indicating that pretreatment with cytarabine, followed by proteasome inhibition, may be the preferred approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available